NASDAQ:OPTN OptiNose Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding OptiNose Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.11 -0.21 (-4.86 %) (As of 09/21/2020 02:52 PM ET) Add Compare Share Today's Range$4.04Now: $4.11▼$4.2650-Day Range$4.27MA: $5.06▼$6.9052-Week Range$3.28Now: $4.11▼$11.66Volume24,747 shsAverage Volume425,620 shsMarket Capitalization$189.03 millionP/E RatioN/ADividend YieldN/ABeta0.73 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It is also developing XHANCE, which is in Phase IIIb clinical trial for the treatment of chronic sinusitis; and OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail (sumatriptan nasal powder) to treat migraine in adults; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingOptiNose has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.50, OptiNose has a forecasted upside of 394.0% from its current price of $4.15.Amount of Analyst CoverageOptiNose has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesOptiNose has received 226 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOptiNose has received 245 “underperform” votes. (Add your “underperform” vote.)Community SentimentOptiNose has received 52.02% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about OptiNose and other stocks. Vote “Outperform” if you believe OPTN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OPTN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOptiNose does not currently pay a dividend.Dividend GrowthOptiNose does not have a long track record of dividend growth. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OptiNose insiders have bought 91.61% more of their company's stock than they have sold. Specifically, they have bought $42,412.00 in company stock and sold $22,134.00 in company stock.Percentage Held by Insiders38.00% of the stock of OptiNose is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.96% of the stock of OptiNose is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OptiNose are expected to grow in the coming year, from ($2.18) to ($1.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptiNose is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptiNose is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOptiNose has a P/B Ratio of 2.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.28 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OPTN Previous Symbol CUSIPN/A CIK1494650 Webwww.optinose.com Phone267-364-3500Debt Debt-to-Equity Ratio8.32 Current Ratio4.27 Quick Ratio4.09Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$34.63 million Price / Sales5.46 Cash FlowN/A Price / Cash FlowN/A Book Value$1.48 per share Price / Book2.78Profitability EPS (Most Recent Fiscal Year)($2.63) Net Income$-110,050,000.00 Net Margins-265.88% Return on Equity-282.14% Return on Assets-66.85%Miscellaneous Employees221 Outstanding Shares45,992,000Market Cap$189.03 million Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $4.11 -0.21 (-4.86 %) (As of 09/21/2020 02:52 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive OPTN News and Ratings via Email Sign-up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter. OptiNose (NASDAQ:OPTN) Frequently Asked Questions How has OptiNose's stock been impacted by Coronavirus? OptiNose's stock was trading at $5.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OPTN shares have decreased by 19.2% and is now trading at $4.09. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of OptiNose? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for OptiNose. When is OptiNose's next earnings date? OptiNose is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for OptiNose. How were OptiNose's earnings last quarter? OptiNose Inc (NASDAQ:OPTN) released its earnings results on Tuesday, August, 4th. The company reported ($0.56) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.56). OptiNose had a negative net margin of 265.88% and a negative return on equity of 282.14%. View OptiNose's earnings history. What price target have analysts set for OPTN? 4 equities research analysts have issued 1 year target prices for OptiNose's shares. Their forecasts range from $17.00 to $25.00. On average, they anticipate OptiNose's share price to reach $20.50 in the next twelve months. This suggests a possible upside of 401.2% from the stock's current price. View analysts' price targets for OptiNose. Are investors shorting OptiNose? OptiNose saw a increase in short interest in August. As of August 31st, there was short interest totaling 7,640,000 shares, an increase of 15.1% from the August 15th total of 6,640,000 shares. Based on an average trading volume of 673,200 shares, the days-to-cover ratio is currently 11.3 days. Approximately 25.1% of the company's shares are sold short. View OptiNose's Short Interest. Who are some of OptiNose's key competitors? Some companies that are related to OptiNose include resTORbio (TORC), Frequency Therapeutics (FREQ), Kadmon (KDMN), Endo International (ENDP), Phibro Animal Health (PAHC), Spectrum Pharmaceuticals (SPPI), Wave Life Sciences (WVE), ImmunoGen (IMGN), Collegium Pharmaceutical (COLL), Emisphere Technologies (EMIS), DiaMedica Therapeutics (DMCAF), Cara Therapeutics (CARA), Omeros (OMER), Syndax Pharmaceuticals (SNDX) and AC Immune (ACIU). View all competitors. What other stocks do shareholders of OptiNose own? Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Proteostasis Therapeutics (PTI), Idera Pharmaceuticals (IDRA), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Matinas BioPharma (MTNB), Dynavax Technologies (DVAX), Flexion Therapeutics (FLXN), Paratek Pharmaceuticals (PRTK), SCYNEXIS (SCYX) and Selecta Biosciences (SELB). Who are OptiNose's key executives? OptiNose's management team includes the following people: Mr. Peter K. Miller, CEO & Director (Age 59, Pay $1.02M)Dr. Ramy A. Mahmoud M.D., M.P.H., Pres & COO (Age 55, Pay $743.72k)Mr. Keith Alan Goldan, Chief Financial Officer (Age 49, Pay $603.73k)Mr. Michael F. Marino, Chief Legal Officer & Corp. Sec. (Age 44, Pay $708.26k)Mr. Jonathan Neely, VP of Investor Relations & Bus. Operations When did OptiNose IPO? (OPTN) raised $101 million in an initial public offering (IPO) on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO. What is OptiNose's stock symbol? OptiNose trades on the NASDAQ under the ticker symbol "OPTN." Who are OptiNose's major shareholders? OptiNose's stock is owned by many different retail and institutional investors. Top institutional shareholders include Thrivent Financial for Lutherans (3.71%), Wasatch Advisors Inc. (2.02%), Paradigm Capital Management Inc. NY (1.62%), Nuveen Asset Management LLC (0.47%), Hudson Bay Capital Management LP (0.43%) and Charles Schwab Investment Management Inc. (0.39%). Company insiders that own OptiNose stock include Avista Capital Partners Ii Gp,, Joseph C Scodari, Michael F Marino III, Peter K Miller, Ramy A Mahmoud and Thomas Edward Gibbs. View institutional ownership trends for OptiNose. Which major investors are selling OptiNose stock? OPTN stock was sold by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, Wasatch Advisors Inc., Marshall Wace LLP, Hudson Bay Capital Management LP, Bank of New York Mellon Corp, UBS Group AG, and First Republic Investment Management Inc.. Company insiders that have sold OptiNose company stock in the last year include Avista Capital Partners Ii Gp,, Peter K Miller, and Ramy A Mahmoud. View insider buying and selling activity for OptiNose. Which major investors are buying OptiNose stock? OPTN stock was purchased by a variety of institutional investors in the last quarter, including Paradigm Capital Management Inc. NY, Nuveen Asset Management LLC, PDT Partners LLC, Bank of America Corp DE, California Public Employees Retirement System, SG Americas Securities LLC, Charles Schwab Investment Management Inc., and State of Wisconsin Investment Board. Company insiders that have bought OptiNose stock in the last two years include Joseph C Scodari, Michael F Marino III, and Peter K Miller. View insider buying and selling activity for OptiNose. How do I buy shares of OptiNose? Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is OptiNose's stock price today? One share of OPTN stock can currently be purchased for approximately $4.09. How big of a company is OptiNose? OptiNose has a market capitalization of $188.11 million and generates $34.63 million in revenue each year. The company earns $-110,050,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. OptiNose employs 221 workers across the globe. What is OptiNose's official website? The official website for OptiNose is www.optinose.com. How can I contact OptiNose? OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected] This page was last updated on 9/21/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
